Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.72 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729580 | 0.84 | PARP1 (0.74) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL1502069 | 0.84 | PARP1 (1.00) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL3360298 | 0.82 | PARP1 (0.72) | PARP1HCRTR1HCRTR2MGLLRORC | |
| Hydrochloric Acid SCHEMBL7265489 | 0.82 | PARP1 (0.72) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL14114432 | 0.81 | PARP1 (0.66) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL21804730 | 0.81 | PARP1 (0.70) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL14880539 | 0.79 | PARP1 (0.68) | PARP1HCRTR1HCRTR2MGLLMAPK14 | |
| SCHEMBL25891319 | 0.79 | PARP1 (0.68) | PARP1HCRTR1HCRTR2MGLLRORC | |
| Oxalic Acid SCHEMBL17978250 | 0.79 | PARP1 (0.90) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL8876227 | 0.78 | PARP1 (0.50) | PARP1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| CN-112010864-B | Vascular endothelial growth factor receptor inhibitor and preparation method and application thereof | 江苏威凯尔医药科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11225478-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| CN-110003200-B | P2X7 modulators | 詹森药业有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-110577546-B | VEGFR inhibitor and preparation method and application thereof | 江苏威凯尔医药科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-112010864-A | Vascular endothelial growth factor receptor inhibitor and preparation method and application thereof | 江苏威凯尔医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-20200325138-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-15 | — | — | US | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| EP-1804786-A2 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006039356-A2 | SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-0994876-B1 | QUATERNARY AMMONIUM COMPOUNDS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2004-09-08 | — | — | EP | disclosed |
| US-6380396-B1 | CHEMICAL INTERMEDIATES FOR ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2002-04-30 | — | — | US | disclosed |
| US-6207678-B1 | USED FOR TREATING INFLAMMATORY DISEASE SUCH AS ARTHRITIS, PSORIASIS, ASTHMA OR INFLAMMATORY BOWEL DISEASE, CENTRAL NERVOUS SYSTEM DISORDER SUCH AS ANXIETY, DEPRESSION, DEMENTIA OR PSYCHOSIS, GASTROINTESTINAL DISORDERS | PFIZER INC | 2001-03-27 | — | — | US | disclosed |
| EP-0994876-A1 | QUATERNARY AMMONIUM COMPOUNDS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998057972-A1 | QUATERNARY AMMONIUM COMPOUNDS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998007722-A1 | QUATERNARY AMMONIUM COMPOUNDS AS TACHYKININ ANTAGONIST | PFIZER LIMITED (GB) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325138-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885HCRTR1 402/4885HCRTR2 128/4885 |
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885HCRTR1 402/4885HCRTR2 128/4885 |
| US-11225478-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885HCRTR1 402/4885HCRTR2 128/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885HCRTR1 402/4885HCRTR2 128/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885HCRTR1 402/4885HCRTR2 128/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885HCRTR1 402/4885HCRTR2 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.